Plain-English translation of NCT05334693 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new immunotherapy approach using expanded haploidentical natural killer cells to help treat acute myeloid leukemia (AML) in children and young adults. Natural killer cells are a type of immune cell that can fight cancer. In this study, doctors will grow large numbers of these cells in the laboratory from a family member donor, then give them to patients after chemotherapy to help prevent the cancer from coming back.
Current treatments for AML work well for some patients, but others still relapse or need additional help staying in remission. This treatment is designed to strengthen the body's immune system to better control the cancer after chemotherapy, potentially improving survival rates.
You likely qualify if…
You likely don't qualify if…
If you enroll, you'll first receive chemotherapy (cyclophosphamide and fludarabine) to prepare your body. Then you'll receive two separate intravenous infusions of the specially grown natural killer cells. A family member who matches your genetics will need to undergo apheresis (a procedure to collect immune cells) so the cells can be grown in the laboratory for you. The trial will monitor how well this approach works and how your body responds to the treatment.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
Belarus
Phase
Safety & dosing / Early efficacy
Sponsor
Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
Enrollment target
~15 participants
Started
November 2021
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
6 Months – 21 Years
Last updated on clinicaltrials.gov in August 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Tatsiana Shman, PhD
Belarussian Research Center for Pediatric Oncology, Hematology and Immunology
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.